Connect your AI

Bruker BRKR Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments

Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments at other companies

Agilent TechnologiesA

——

IlluminaILMN

——

Bio-Rad LaboratoriesBIO

——

Other financials

Income statement

Revenue$823.4M+2.7%

Gross profit$379.8M-2.9%

Operating income$10.2M-67.9%

Net income$14.4M-17.2%

EPS (diluted)$0.02-81.8%

Balance sheet

Cash & equivalents$137.6M-26.7%

Total debt$1.7B-20.9%

Total equity$2.5B+34.6%

Total assets$6.1B+3.3%

Cash flow

Operating cash flow$71.2M+9.5%

CapEx$24.2M-6.9%

Free cash flow$47.0M+20.5%

Valuation

Market cap$8.71B-13.2%

Enterprise value$10.25B-14.9%

P/S2.5×-0.4×

Profitability

Gross margin45.3%-3.7pp

Operating margin1.3%-5.0pp

Net margin-0.6%-10.0pp

FCF margin1.5%-3.6pp

Returns & leverage

Return on equity-1%-21.2pp

Debt / equity0.7×-0.5×

Current ratio1.6×0.0×

Where this comes from

Reported directly by Bruker in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount.

The official record: Bruker’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bruker's equity securities without readily determinable fair value - cumulative downward adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Bruker's equity securities without readily determinable fair value - cumulative downward adjustments?: Bruker (BRKR) reported equity securities without readily determinable fair value - cumulative downward adjustments of $25.9M in Q1 2026.
How has Bruker's equity securities without readily determinable fair value - cumulative downward adjustments changed year-over-year?: Bruker's equity securities without readily determinable fair value - cumulative downward adjustments decreased by 24.3% year-over-year, from $34.2M to $25.9M.